Breast Cancer Update

Dr Priyanka Sharma from The University of Kansas Cancer Center in Westwood, Kansas, summarizes the treatment landscape for patients with breast cancer and discusses the implications of recently presented clinical findings from the ESMO Congress 2025.  CME information and select publications here .

Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville, Tennessee, reviews available clinical data with PROTAC estrogen receptor degraders and their potential role in the management of HR-positive metastatic breast cancer.  CME information and select publications here .

Prof Francois-Clement Bidard from the Institut Curie in Paris, France, Dr Hope S Rugo from the City of Hope Comprehensive Cancer Center in Duarte, California, Dr Rebecca Shatsky from the University of California San Diego Moores Cancer Center and Dr Seth Wander from Massachusetts General Hospital in Boston discuss recent updates on available and emerging treatment strategies involving oral SERDs f...

Dr Harold J Burstein, Dr Matthew P Goetz, Dr Heather McArthur and Dr Rita Nanda share their perspectives on the evolving therapeutic landscape for patients with breast cancer.  CME information and select publications here .

Prof Patrick Neven from University Hospitals Leuven in Leuven, Belgium, discusses recent updates on available and novel treatment strategies with oral SERDs for ER-positive metastatic breast cancer.    CME information and select publications here .

Kevin Kalinsky from Winship Cancer Institute of Emory University in Atlanta, Georgia, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of breast cancer.  CME information and select publications here .

Dr Aditya Bardia and Dr Adam M Brufsky discuss published and emerging datasets investigating the incorporation of antibody-drug conjugates into the treatment of metastatic breast cancer. CME information and select publications here .

Dr Laura Huppert from the University of California, San Francisco, discusses approved and investigational antibody-drug conjugates in the current and future management of HR-positive and triple-negative metastatic breast cancer.  CME information and select publications here .

Dr Sara A Hurvitz and Dr Sara M Tolaney summarize the treatment landscape for breast cancer and discuss the implications of clinical findings recently presented at the 2025 ASCO Annual Meeting.  CME information and select publications here .

Dr Kevin Kalinsky from the Winship Cancer Institute of Emory University in Atlanta, Georgia, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of breast cancer.  CME information and select publications here .

Prof Peter Schmid from Barts Cancer Institute in London reviews available efficacy and safety data guiding the optimal management of metastatic triple-negative breast cancer.  CME information and select publications here .

Dr Ana C Garrido-Castro and Prof Peter Schmid review patient cases and provide insights regarding the treatment of metastatic triple-negative breast cancer.   CME information and select publications here .

Dr Neel Pasricha from the University of California, San Franciso, reviews corneal and other ophthalmic toxicities associated with antibody-drug conjugates and other cancer therapies and strategies for their prevention and management.    CME information and select publications here .

Prof Rebecca A Dent from National Cancer Centre Singapore, Dr Hans Lee from Sara Cannon Research Institute in Nashville, Tennessee, Dr Neel Pasricha from the University of California, San Francisco, and Dr Tiffany A Richards from The University of Texas MD Anderson Cancer Center in Houston, discuss strategies to manage ocular toxicities associated with antibody-drug conjugates and other cancer the...

Dr Komal Jhaveri from Memorial Sloan Kettering Cancer Center in New York, New York, and Dr Virginia Kaklamani from UT Health San Antonio MD Anderson Cancer Center in Texas review available efficacy and safety data guiding the optimal integration of oral SERDs into clinical practice.  CME information and select publications here .

Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville, Tennessee, discusses the monitoring, mitigation and management of adverse events with available antibody-drug conjugates and novel strategies incorporating ADCs into the breast cancer treatment paradigm.   CME information and select publications here .

Dr Sarah Sammons from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses cases and reviews the current management of brain metastases in patients with HER2-positive breast cancer.  CME information and select publications here .

Dr Erika Hamilton from Sarah Cannon Research Institute in Nashville, Tennessee, discusses available data and shares clinical investigator perspectives on the role of TROP2-directed antibody-drug conjugates in the management of HR-positive and triple-negative breast cancers.  CME information and select publications here .

Dr Hope S Rugo from City of Hope Comprehensive Cancer Center in Duarte, California, discusses the efficacy and safety of approved and investigational antibody-drug conjugates for endocrine-resistant HR-positive and triple-negative metastatic breast cancer.  CME information and select publications here .

Dr Harold Burstein, Dr Javier Cortés, Prof Rebecca A Dent, Dr Kevin Kalinsky, Dr Joyce O’Shaughnessy and moderator Dr Hope S Rugo present data informing treatment decision-making for patients with metastatic breast cancer at the 2025 ASCO annual meeting.  CME information and select publications here .

Dr Patrick Wen from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses the current and future management of IDH-mutant gliomas.   CME information and select publications here .

Drs Virginia F Borges and Seth Wander summarize the treatment landscape for patients with hormone receptor-positive breast cancer, supported with clinical perspectives and management strategies from nurse practitioners Ms Jamie Carroll and Mr Ronald Stein.  NCPD information and select publications here .

Dr Ian Krop from Yale Cancer Center in New Haven, Connecticut, and Dr Sara Tolaney from Dana-Farber Cancer Institute in Boston, Massachusetts, summarize major treatment advances over the past year and review relevant ongoing clinical trials for patients with breast cancer.  CME information and select publications here .

Dr Rinath Jeselsohn from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer.  CME information and select publications here .

Dr Rinath M Jeselsohn from the Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with oral SERDs in the management of ER-positive metastatic breast cancer.  CME information and select publications here .